Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens.

Publication ,  Journal Article
Doney, K; Storb, R; Buckner, CD; McGuffin, R; Witherspoon, R; Deeg, HJ; Appelbaum, FR; Sullivan, KM; Thomas, ED
Published in: Exp Hematol
March 1987

A total of 46 patients with aplastic anemia (34 severe; 12 moderate) were treated with antihuman thymocyte globulin (ATG), high-dose methylprednisolone, and oxymetholone. Early symptoms of ATG toxicity included fever, rash, and bronchospasm. Signs of serum sickness also developed in 23 patients. Complications associated with high doses of steroids were hyperglycemia, hypertension, fluid retention, gastrointestinal hemorrhage, and aseptic necrosis of the hip. Other morbidity possible associated with steroid administration included seizures, arrhythmias, and headache with papilledema. Studies of elevated liver function necessitated discontinuation of androgen therapy in eight patients. A complete or partial hematological response was noted in 19 patients (41%). Of these, three have had recurrent cytopenias, of whom one has developed a myelodysplastic syndrome. There are currently 34 patients surviving, and 12 who have died. Actuarial survival at three years is 65%. These response and survival data are comparable to those of previous trials using ATG and androgens without high-dose steroids. A prospective, randomized trial is needed to determine whether the addition of high-dose corticosteroids to ATG does significantly increase the rate and frequency of response in order to justify the toxicity of this additional immunosuppressive therapy in the treatment of aplastic anemia.

Duke Scholars

Published In

Exp Hematol

ISSN

0301-472X

Publication Date

March 1987

Volume

15

Issue

3

Start / End Page

239 / 242

Location

Netherlands

Related Subject Headings

  • T-Lymphocytes
  • Oxymetholone
  • Myelodysplastic Syndromes
  • Methylprednisolone
  • Immunosuppression Therapy
  • Immunology
  • Humans
  • Female
  • Dose-Response Relationship, Drug
  • Antilymphocyte Serum
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Doney, K., Storb, R., Buckner, C. D., McGuffin, R., Witherspoon, R., Deeg, H. J., … Thomas, E. D. (1987). Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens. Exp Hematol, 15(3), 239–242.
Doney, K., R. Storb, C. D. Buckner, R. McGuffin, R. Witherspoon, H. J. Deeg, F. R. Appelbaum, K. M. Sullivan, and E. D. Thomas. “Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens.Exp Hematol 15, no. 3 (March 1987): 239–42.
Doney K, Storb R, Buckner CD, McGuffin R, Witherspoon R, Deeg HJ, et al. Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens. Exp Hematol. 1987 Mar;15(3):239–42.
Doney, K., et al. “Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens.Exp Hematol, vol. 15, no. 3, Mar. 1987, pp. 239–42.
Doney K, Storb R, Buckner CD, McGuffin R, Witherspoon R, Deeg HJ, Appelbaum FR, Sullivan KM, Thomas ED. Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens. Exp Hematol. 1987 Mar;15(3):239–242.
Journal cover image

Published In

Exp Hematol

ISSN

0301-472X

Publication Date

March 1987

Volume

15

Issue

3

Start / End Page

239 / 242

Location

Netherlands

Related Subject Headings

  • T-Lymphocytes
  • Oxymetholone
  • Myelodysplastic Syndromes
  • Methylprednisolone
  • Immunosuppression Therapy
  • Immunology
  • Humans
  • Female
  • Dose-Response Relationship, Drug
  • Antilymphocyte Serum